Skye Bioscience Inc. Information

View Top Employees from Skye Bioscience Inc.

Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

Website	http://www.skyebioscience.com
Ticker	NMUS
Revenue	$606000
Funding	$16.6 million
Employees	18 (1 on RocketReach)
Founded	2011
Address	12250 El Camino Real Drive Suite 100, San Diego, California 92130, US
Phone	+1 949-396-0330
Industry	Biotechnology Research, Drug Manufacturing & Research, Biopharma, Pharmaceuticals, Biotechnology, Healthcare, Health Care, Science and Engineering, Pharmaceutical
Keywords	Drug Development, Biologics, Metabolic Health, Pharmaceutical Research, Therapeutic Molecules, Biopharmaceutical, Drug Discovery, Biotechnology, Pharmaceutical, Therapeutics, Molecular Pathways, Precision Medicine, Innovative Therapies, Gpcrs, Bioscience, Clinical Trials, Health Solutions
Competitors	Trulieve, Curaleaf, Green Thumb Industries (GTI), Verano, Canopy Growth Corporation, Charlotte's Web, MedMen, CV Sciences, Inc., Zynerba Pharmaceuticals, Dixie Brands, Inc. +27 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 49 Companies